188 related articles for article (PubMed ID: 37095423)
1. Deleted in lymphocytic leukemia 2 (DLEU2): a possible biomarker that holds promise for future diagnosis and treatment of cancer.
Qu X; Cao YX; Xing YX; Liu Q; Li HJ; Yang WH; Wang BQ; Han SY; Wang YS
Clin Transl Oncol; 2023 Oct; 25(10):2772-2782. PubMed ID: 37095423
[TBL] [Abstract][Full Text] [Related]
2. DLEU2: A Meaningful Long Noncoding RNA in Oncogenesis.
Xu W; Wang B; Cai Y; Guo C; Liu K; Yuan C
Curr Pharm Des; 2021; 27(20):2337-2343. PubMed ID: 33106136
[TBL] [Abstract][Full Text] [Related]
3. Long noncoding RNA DLEU2 predicts a poor prognosis and enhances malignant properties in laryngeal squamous cell carcinoma through the miR-30c-5p/PIK3CD/Akt axis.
Li X; Xu F; Meng Q; Gong N; Teng Z; Xu R; Zhao M; Xia M
Cell Death Dis; 2020 Jun; 11(6):472. PubMed ID: 32555190
[TBL] [Abstract][Full Text] [Related]
4. Long non-coding RNA DLEU2 promotes the progression of esophageal cancer through miR-30e-5p/E2F7 axis.
Lu T; Wang R; Cai H; Cui Y
Biomed Pharmacother; 2020 Mar; 123():109650. PubMed ID: 31884338
[TBL] [Abstract][Full Text] [Related]
5. LncRNA DLEU2 accelerates the tumorigenesis and invasion of non-small cell lung cancer by sponging miR-30a-5p.
Wu W; Zhao Y; Gao E; Li Y; Guo X; Zhao T; He W; Zhang H
J Cell Mol Med; 2020 Jan; 24(1):441-450. PubMed ID: 31721438
[TBL] [Abstract][Full Text] [Related]
6. LncRNA DLEU2 is activated by STAT1 and induces gastric cancer development via targeting miR-23b-3p/NOTCH2 axis and Notch signaling pathway.
Li G; Zhang Z; Chen Z; Liu B; Wu H
Life Sci; 2021 Jul; 277():119419. PubMed ID: 33785336
[TBL] [Abstract][Full Text] [Related]
7. LncRNA DLEU2 silencing impedes the migration, invasion and EMT in gastric cancer cell by suppressing PI3K/AKT signaling pathway.
Hu J; Wang M; Yang Y; Xing Y; Li S
Immunopharmacol Immunotoxicol; 2022 Oct; 44(5):719-731. PubMed ID: 35736813
[No Abstract] [Full Text] [Related]
8. Deleted in lymphocytic leukemia 2 (DLEU2): An lncRNA with dissimilar roles in different cancers.
Ghafouri-Fard S; Dashti S; Farsi M; Taheri M
Biomed Pharmacother; 2021 Jan; 133():111093. PubMed ID: 33378985
[TBL] [Abstract][Full Text] [Related]
9. lncRNA DLEU2 modulates cell proliferation and invasion of non-small cell lung cancer by regulating miR-30c-5p/SOX9 axis.
Zhou Y; Shi H; Du Y; Zhao G; Wang X; Li Q; Liu J; Ye L; Shen Z; Guo Y; Huang Y
Aging (Albany NY); 2019 Sep; 11(18):7386-7401. PubMed ID: 31541993
[TBL] [Abstract][Full Text] [Related]
10. lncRNA DLEU2 Accelerates Oral Cancer Progression via miR-30a-5p/RAP1B Axis to Regulate p38 MAPK Signaling Pathway.
Zhang W; Wang Y; Xu P; Du Y; Guan W
Dis Markers; 2022; 2022():9310048. PubMed ID: 36277988
[TBL] [Abstract][Full Text] [Related]
11. Deleted in lymphocytic leukemia 2 induces retinoic acid receptor beta promoter methylation and mitogen activated kinase-like protein activation to enhance viability and mobility of colorectal cancer cells.
Fu L; Shi Z; Chen B
Bioengineered; 2022 May; 13(5):12847-12862. PubMed ID: 35611845
[TBL] [Abstract][Full Text] [Related]
12. Long non-coding RNA Dleu2 affects proliferation, migration and invasion ability of laryngeal carcinoma cells through triggering miR-16-1 pathway.
Xie ZZ; Xiao ZC; Song YX; Li W; Tan GL
Eur Rev Med Pharmacol Sci; 2018 Apr; 22(7):1963-1970. PubMed ID: 29687850
[TBL] [Abstract][Full Text] [Related]
13. Long noncoding RNA DLEU2 regulates the progression of Wilm's tumor via miR-539-3p/HOXB2 axis.
Yong J; He J; Ning F
J Pediatr Urol; 2023 Feb; 19(1):25-32. PubMed ID: 36209036
[TBL] [Abstract][Full Text] [Related]
14. LncRNA DLEU2 aggravates the progression of hepatocellular carcinoma through binding to EZH2.
Guo Y; Bai M; Lin L; Huang J; An Y; Liang L; Liu Y; Huang W
Biomed Pharmacother; 2019 Oct; 118():109272. PubMed ID: 31376657
[TBL] [Abstract][Full Text] [Related]
15. LncRNA DLEU2 promotes cervical cancer cell proliferation by regulating cell cycle and NOTCH pathway.
He M; Wang Y; Cai J; Xie Y; Tao C; Jiang Y; Li H; Song F
Exp Cell Res; 2021 May; 402(1):112551. PubMed ID: 33675808
[TBL] [Abstract][Full Text] [Related]
16. E2F transcription factor 2-activated DLEU2 contributes to prostate tumorigenesis by upregulating serum and glucocorticoid-induced protein kinase 1.
Li P; Xu H; Yang L; Zhan M; Shi Y; Zhang C; Gao D; Gu M; Chen Y; Wang Z
Cell Death Dis; 2022 Jan; 13(1):77. PubMed ID: 35075115
[TBL] [Abstract][Full Text] [Related]
17. LncRNA DLEU2 promotes tumour growth by sponging miR-337-3p in human osteosarcoma.
Liu W; Liu PC; Ma K; Wang YY; Chi QB; Yan M
Cell Biochem Funct; 2020 Oct; 38(7):886-894. PubMed ID: 32196715
[TBL] [Abstract][Full Text] [Related]
18. Long non-coding RNA DLEU2 drives EMT and glycolysis in endometrial cancer through HK2 by competitively binding with miR-455 and by modulating the EZH2/miR-181a pathway.
Dong P; Xiong Y; Konno Y; Ihira K; Kobayashi N; Yue J; Watari H
J Exp Clin Cancer Res; 2021 Jun; 40(1):216. PubMed ID: 34174908
[TBL] [Abstract][Full Text] [Related]
19. AGAP2-AS1: An Indispensable lncRNA in Tumors.
Chen J; Wang B
Mini Rev Med Chem; 2023; 23(3):336-342. PubMed ID: 35708074
[TBL] [Abstract][Full Text] [Related]
20. Silencing of DLEU2 suppresses pancreatic cancer cell proliferation and invasion by upregulating microRNA-455.
Xu B; Gong X; Zi L; Li G; Dong S; Chen X; Li Y
Cancer Sci; 2019 May; 110(5):1676-1685. PubMed ID: 30838724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
